Wednesday, July 8, 2026

pharma · Hypoparathyroidism · Postbariatric Hypoglycemia · MBX

MBX Biosciences

MBX Biosciences is a pharma organization headquartered in Carmel, USA. It trades on NYSE under ticker MBX. Primary therapeutic focus areas include Hypoparathyroidism, Postbariatric Hypoglycemia, Renal Impairment, Obesity

Carmel, USA HQ
2019 Founded
74 Employees
Public company Type
MBX · NYSE Ticker
Company details
Clinical program

MBX 2109 (Part A)

Phase 1 · small molecule · Healthy

MBX 2109 (Part A) for Healthy is a Phase 1 program (small_molecule) at MBX Biosciences with 1 ClinicalTrials.gov record(s).

← All MBX Biosciences projects Phase 1 small molecule completed

Internal code MBX-2H1001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
MBX Biosciences
Phase
Phase 1
Modality
small_molecule
Indication
Healthy
Status
completed
Trials
1

Clinical trials